Chemtai Mungo, MD, MPH, and Lisa Rahangdale, MD, MPH, presented at the American Society for Colposcopy and Cervical Pathology (ASCCP) meeting on May 4, focusing on the latest advancements in topical therapies for cervical pre-cancer treatment in the U.S. and around the world.
Dr. Mungo and Dr. Rahangdale, both obstetricians/gynecologists and clinical researchers, provided a review of their ongoing studies. They also shared the latest guidelines concerning topical therapies for the treatment of cervical pre-cancer, including innovative approaches and global perspectives for cervical pre-cancer management.
Additionally, Dr. Mungo delivered a virtual oral presentation on the acceptability of self-administered topical therapies among African women. She also showcased a poster on her recent pilot trial, which explored the safety of self-administered intravaginal 5-Fluorouracil cream as adjuvant therapy following treatment for CIN2/3 among women living with HIV in Kenya. Dr. Rahangdale participated in a panel discussion for the National Cancer Institute’s Last Mile Initiative, which aims to address the barrier of FDA approval for self-collection approaches for HPV testing-based cervical cancer treatment.
Dr. Rahangdale is a professor, and Dr. Mungo is an assistant professor of obstetrics and gynecology, and both are members of the Institute for Global Health and Infectious Diseases (IGHID), the Center for AIDS Research (CFAR), and the UNC Lineberger Comprehensive Cancer Center. They are at the forefront of research and clinical practice, driving advancements to improve the prevention and treatment of cervical cancer globally.
